SWM
NBIX icon

SHP Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

SHP Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98K Buy
15
+12
+400% +$1.59K ﹤0.01% 1280
2025
Q4 		$426 Buy
+3
New +$435 ﹤0.01% 1386

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SHP Wealth Management's NBIX Position: Q1 2026 in Review

SHP Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 400% in Q1 2026, buying an estimated $1.59K and bringing the position to 15 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

SHP Wealth Management first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • SHP Wealth Management held 15 shares of Neurocrine Biosciences worth $1.98K as of Q1 2026.
  • SHP Wealth Management bought 12 Neurocrine Biosciences shares in Q1 2026, an estimated $1.59K.
  • Neurocrine Biosciences made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1280 holding.
  • SHP Wealth Management first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.